Intercure Ltd (INCR) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

InterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platforms with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61 million (Approximately 17% of revenues), as compared to an...

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

Revenues for H2 2023 were affected by damages caused by the terrorist attack on October 7, 2023 and the war in Gaza. However, InterCure it is...

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

InterCure provides an update following recent Cannabis Reform in Germany Expects to launch its first products in Germany in the coming months...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]